Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial

Affiliations

¹ Department of Radiation Medicine, Oregon Health & Science University, Portland.
² Department of Radiation Oncology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota.
³ University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.

Clinical Trial

Aaron J Grossberg et al. JAMA Oncol. 2023.

. 2023 Feb 1;9(2):275.

doi: 10.1001/jamaoncol.2022.6135.

¹ Department of Radiation Medicine, Oregon Health & Science University, Portland.
² Department of Radiation Oncology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota.
³ University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.

No abstract available

Comment on

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Katz MHG, et al. JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319. JAMA Oncol. 2022. PMID: 35834226 Free PMC article. Clinical Trial.